Holen Sie sich die Stockscreener-App
16.23
4.98%
-0.85
Handel nachbörslich:
16.23
Schlusskurs vom Vortag:
$17.08
Offen:
$17.08
24-Stunden-Volumen:
863.72K
Relative Volume:
0.67
Marktkapitalisierung:
$1.34B
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-8.9176
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
-7.15%
1M Leistung:
-4.98%
6M Leistung:
+48.08%
1J Leistung:
+78.16%
1-Tages-Spanne:
$16.17
$17.38
1-Wochen-Bereich:
$16.17
$18.20
52-Wochen-Spanne:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Vergleichen Sie EYPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
16.23 | 1.41B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2025 Technical Patterns & Safe Capital Growth Stock Tips - ulpravda.ru
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Weekly Recap & AI Driven Price Predictions - ulpravda.ru
Will EyePoint Pharmaceuticals Inc. stock remain a Wall Street favoriteGrip and Outsole Review & road comfort picks for daily use - ulpravda.ru
How sustainable is EyePoint Pharmaceuticals Inc. stock dividend payoutMarket Performance Report & Safe Entry Point Identification - ulpravda.ru
How EyePoint Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Gainers & Real-Time Volume Analysis Alerts - ulpravda.ru
Aug Ideas: Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikes2025 Year in Review & Safe Investment Capital Preservation Plans - ulpravda.ru
Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Value Summary & High Conviction Buy Zone Alerts - ulpravda.ru
Will EyePoint Pharmaceuticals Inc. stock continue dividend increasesMarket Volume Report & Entry Point Confirmation Alerts - ulpravda.ru
Eyepoint Insider Sold Shares Worth $727,319, According to a Recent SEC Filing - MarketScreener
EyePoint Chief Medical Officer Sells All Common Stock Holdings - TradingView — Track All Markets
EyePoint, Inc.Common Stock (NQ: EYPT - FinancialContent
Mizuho reiterates Outperform rating on EyePoint stock with $33 target - Investing.com
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target - Investing.com Nigeria
Mizuho reiterates Outperform rating on EyePoint stock with $33 target By Investing.com - Investing.com India
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target By Investing.com - Investing.com India
EyePoint’s Phase 3 trials for DURAVYU in wet AMD on track for mid-2026 data - Investing.com
EyePoint, Inc. Advances DURAVYU in Pivotal Phase 3 Trials for Wet AMD and DME with Key Milestones Expected in 2026 - Quiver Quantitative
Uveitis Treatment Market to Reach US$ 1,258.35million | CAGR - openPR.com
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 - GlobeNewswire Inc.
PRN_FinancialWrapper | PR NewswireEyePoint, Inc.Common Stock (Nasdaq:EYPT) Stock Quote - FinancialContent
EYPT (EyePoint) Days Payable : 1,883.28 (As of Sep. 2025) - GuruFocus
Is EyePoint Pharmaceuticals the Next Sleeper Stock Legend or Just Overhyped Noise? - AD HOC NEWS
Institutional Investors in EyePoint, Inc. (NASDAQ:EYPT) See US$67m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
What drives EyePoint Pharmaceuticals Inc PV3B stock priceSell Signals and Alerts & Top Analyst Picks Available for Free - earlytimes.in
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1%Here's What Happened - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Understanding the Setup: (EYPT) and Scalable Risk - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
127,489 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Corient Private Wealth LLC - MarketBeat
Why EyePoint (EYPT) Is Up 9.6% After Upbeat Earnings Revisions And Momentum SignalsAnd What's Next - Sahm
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2%Time to Sell? - MarketBeat
EyePoint Earnings Notes - Trefis
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know - Yahoo Finance
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - Zacks Investment Research
Would You Still Hold EyePoint Stock If It Fell 30%? - Trefis
Will EyePoint Pharmaceuticals Inc. stock rally after Fed decisionsWeekly Risk Summary & Technical Analysis for Trade Confirmation - Улправда
EyePoint (EYPT) Price Target Increased by 10.87% to 36.80 - Nasdaq
Is EyePoint Pharmaceuticals Inc. stock dividend yield sustainable2025 Technical Overview & Expert Approved Momentum Ideas - Улправда
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Rating Increased to Strong-Buy at TD Cowen - MarketBeat
Why (EYPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside - Barchart.com
Can EyePoint Pharmaceuticals Inc. stock resist market sell offsMarket Risk Summary & High Conviction Buy Zone Picks - Улправда
Is EyePoint Pharmaceuticals Inc a good long term investmentOptions Trading Strategies & Free Tap Rapid Wealth - earlytimes.in
Will EyePoint Pharmaceuticals Inc. stock reach all time highs in 2025 - DonanımHaber
Inflation Data: How EyePoint Pharmaceuticals Inc. (PV3B) stock compares with market leadersJuly 2025 Sentiment & Community Trade Idea Sharing Platform - Улправда
How EyePoint Pharmaceuticals Inc. stock reacts to oil pricesWeekly Stock Recap & Expert Approved Trade Ideas - DonanımHaber
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025July 2025 Rallies & Low Risk Growth Stock Ideas - Улправда
Support Test: Will EyePoint Pharmaceuticals Inc. stock see PE expansionDividend Hike & Low Risk Entry Point Guides - Улправда
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Finanzdaten der Eyepoint Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Eyepoint Inc-Aktie (EYPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Duker Jay S. | President and CEO |
Jan 06 '26 |
Option Exercise |
0.00 |
20,793 |
0 |
87,806 |
| Elston George | Chief Financial Officer |
Jan 06 '26 |
Option Exercise |
0.00 |
15,285 |
0 |
96,339 |
| Ribeiro Ramiro | Chief Medical Officer |
Jan 05 '26 |
Option Exercise |
8.26 |
29,250 |
241,605 |
42,544 |
| Ribeiro Ramiro | Chief Medical Officer |
Jan 05 '26 |
Sale |
17.10 |
42,544 |
727,319 |
0 |
| Ribeiro Ramiro | Chief Medical Officer |
Jan 03 '26 |
Option Exercise |
0.00 |
19,667 |
0 |
19,667 |
| Duker Jay S. | President and CEO |
Jan 05 '26 |
Option Exercise |
0.00 |
30,000 |
0 |
81,518 |
| Duker Jay S. | President and CEO |
Jan 03 '26 |
Option Exercise |
0.00 |
65,000 |
0 |
74,965 |
| Elston George | Chief Financial Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
15,000 |
0 |
85,457 |
| Elston George | Chief Financial Officer |
Jan 03 '26 |
Option Exercise |
0.00 |
19,667 |
0 |
76,781 |
| Lurker Nancy | Director |
Jan 05 '26 |
Option Exercise |
0.00 |
12,666 |
0 |
219,213 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):